Global Lysosomal Storage Disease (LSD) 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI09247125

Publication Date:

September 12, 2024

Pages:

111

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Lysosomal Storage Disease (LSD) market size was valued at US$ 7274.9 million in 2023. With growing demand in downstream market, the Lysosomal Storage Disease (LSD) is forecast to a readjusted size of US$ 10290 million by 2030 with a CAGR of 5.1% during review period.
The research report highlights the growth potential of the global Lysosomal Storage Disease (LSD) market. Lysosomal Storage Disease (LSD) are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Lysosomal Storage Disease (LSD). 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Lysosomal Storage Disease (LSD) market.
Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Disorder. Further Lipid Metabolism Disorder is categorized into Gaucher disease & Fabry disease and Glycoprotein Metabolism Disorder into Pompe disease. LSD develops mainly due to deficiency of lysosomal enzyme in the living body. A person suffering from LSD could experience problems like abnormal growth of bones, delay movement of body, deafness, blindness, dementia, respiratory problems, fatigue/weakness, bone & joint deformity, organ enlargement, lung dysfunction, severe & fatal physical & mental health deterioration.
The global LSD market is expected to grow with growing Ashkenazi (Eastern and Western Europe) population, increasing pharmaceutical R&D spending, growing disposable income, rising healthcare expenditure and accelerating economic growth. Key trends of this rare disease market includes progressing drugs under pipeline and increasing preference towards gene therapy. However, there are some factors which can hinder growth of the market including stringent regulations and limited access to patent rights.
Key Features:
The report on Lysosomal Storage Disease (LSD) market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Lysosomal Storage Disease (LSD) market. It may include historical data, market segmentation by Type (e.g., Lipid Metabolism Disorder, Glycoprotein Metabolism Disorder), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Lysosomal Storage Disease (LSD) market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Lysosomal Storage Disease (LSD) market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Lysosomal Storage Disease (LSD) industry. This include advancements in Lysosomal Storage Disease (LSD) technology, Lysosomal Storage Disease (LSD) new entrants, Lysosomal Storage Disease (LSD) new investment, and other innovations that are shaping the future of Lysosomal Storage Disease (LSD).
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Lysosomal Storage Disease (LSD) market. It includes factors influencing customer ' purchasing decisions, preferences for Lysosomal Storage Disease (LSD) product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Lysosomal Storage Disease (LSD) market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Lysosomal Storage Disease (LSD) market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Lysosomal Storage Disease (LSD) market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Lysosomal Storage Disease (LSD) industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Lysosomal Storage Disease (LSD) market.
麻豆原创 Segmentation:
Lysosomal Storage Disease (LSD) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Lipid Metabolism Disorder
Glycoprotein Metabolism Disorder
Segmentation by application
Hospitals
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Actelion Pharmaceuticals
Amicus Therapeutics
Arena Pharmaceuticals
Astellas Pharma
Astrazeneca
Biomarin Pharmaceutical
Eli Lilly
Lexicon Pharmaceuticals
Novo Nordisk
Merck

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Lysosomal Storage Disease (LSD) 麻豆原创 Size 2019-2030
2.1.2 Lysosomal Storage Disease (LSD) 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Lysosomal Storage Disease (LSD) Segment by Type
2.2.1 Lipid Metabolism Disorder
2.2.2 Glycoprotein Metabolism Disorder
2.3 Lysosomal Storage Disease (LSD) 麻豆原创 Size by Type
2.3.1 Lysosomal Storage Disease (LSD) 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Lysosomal Storage Disease (LSD) 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Lysosomal Storage Disease (LSD) Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Others
2.5 Lysosomal Storage Disease (LSD) 麻豆原创 Size by Application
2.5.1 Lysosomal Storage Disease (LSD) 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Lysosomal Storage Disease (LSD) 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Lysosomal Storage Disease (LSD) 麻豆原创 Size by Player
3.1 Lysosomal Storage Disease (LSD) 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Lysosomal Storage Disease (LSD) Revenue by Players (2019-2024)
3.1.2 Global Lysosomal Storage Disease (LSD) Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Lysosomal Storage Disease (LSD) Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Lysosomal Storage Disease (LSD) by Regions
4.1 Lysosomal Storage Disease (LSD) 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Lysosomal Storage Disease (LSD) 麻豆原创 Size Growth (2019-2024)
4.3 APAC Lysosomal Storage Disease (LSD) 麻豆原创 Size Growth (2019-2024)
4.4 Europe Lysosomal Storage Disease (LSD) 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Lysosomal Storage Disease (LSD) 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Lysosomal Storage Disease (LSD) 麻豆原创 Size by Country (2019-2024)
5.2 Americas Lysosomal Storage Disease (LSD) 麻豆原创 Size by Type (2019-2024)
5.3 Americas Lysosomal Storage Disease (LSD) 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Lysosomal Storage Disease (LSD) 麻豆原创 Size by Region (2019-2024)
6.2 APAC Lysosomal Storage Disease (LSD) 麻豆原创 Size by Type (2019-2024)
6.3 APAC Lysosomal Storage Disease (LSD) 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Lysosomal Storage Disease (LSD) by Country (2019-2024)
7.2 Europe Lysosomal Storage Disease (LSD) 麻豆原创 Size by Type (2019-2024)
7.3 Europe Lysosomal Storage Disease (LSD) 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Lysosomal Storage Disease (LSD) by Region (2019-2024)
8.2 Middle East & Africa Lysosomal Storage Disease (LSD) 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Lysosomal Storage Disease (LSD) 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.1 Global Lysosomal Storage Disease (LSD) Forecast by Regions (2025-2030)
10.1.1 Global Lysosomal Storage Disease (LSD) Forecast by Regions (2025-2030)
10.1.2 Americas Lysosomal Storage Disease (LSD) Forecast
10.1.3 APAC Lysosomal Storage Disease (LSD) Forecast
10.1.4 Europe Lysosomal Storage Disease (LSD) Forecast
10.1.5 Middle East & Africa Lysosomal Storage Disease (LSD) Forecast
10.2 Americas Lysosomal Storage Disease (LSD) Forecast by Country (2025-2030)
10.2.1 United States Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.2.2 Canada Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.2.3 Mexico Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.2.4 Brazil Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.3 APAC Lysosomal Storage Disease (LSD) Forecast by Region (2025-2030)
10.3.1 China Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.3.2 Japan Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.3.3 Korea Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.3.4 Southeast Asia Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.3.5 India Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.3.6 Australia Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.4 Europe Lysosomal Storage Disease (LSD) Forecast by Country (2025-2030)
10.4.1 Germany Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.4.2 France Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.4.3 UK Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.4.4 Italy Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.4.5 Russia Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.5 Middle East & Africa Lysosomal Storage Disease (LSD) Forecast by Region (2025-2030)
10.5.1 Egypt Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.5.2 South Africa Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.5.3 Israel Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.5.4 Turkey Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.5.5 GCC Countries Lysosomal Storage Disease (LSD) 麻豆原创 Forecast
10.6 Global Lysosomal Storage Disease (LSD) Forecast by Type (2025-2030)
10.7 Global Lysosomal Storage Disease (LSD) Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Actelion Pharmaceuticals
11.1.1 Actelion Pharmaceuticals Company Information
11.1.2 Actelion Pharmaceuticals Lysosomal Storage Disease (LSD) Product Offered
11.1.3 Actelion Pharmaceuticals Lysosomal Storage Disease (LSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Actelion Pharmaceuticals Main Business Overview
11.1.5 Actelion Pharmaceuticals Latest Developments
11.2 Amicus Therapeutics
11.2.1 Amicus Therapeutics Company Information
11.2.2 Amicus Therapeutics Lysosomal Storage Disease (LSD) Product Offered
11.2.3 Amicus Therapeutics Lysosomal Storage Disease (LSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Amicus Therapeutics Main Business Overview
11.2.5 Amicus Therapeutics Latest Developments
11.3 Arena Pharmaceuticals
11.3.1 Arena Pharmaceuticals Company Information
11.3.2 Arena Pharmaceuticals Lysosomal Storage Disease (LSD) Product Offered
11.3.3 Arena Pharmaceuticals Lysosomal Storage Disease (LSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Arena Pharmaceuticals Main Business Overview
11.3.5 Arena Pharmaceuticals Latest Developments
11.4 Astellas Pharma
11.4.1 Astellas Pharma Company Information
11.4.2 Astellas Pharma Lysosomal Storage Disease (LSD) Product Offered
11.4.3 Astellas Pharma Lysosomal Storage Disease (LSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Astellas Pharma Main Business Overview
11.4.5 Astellas Pharma Latest Developments
11.5 Astrazeneca
11.5.1 Astrazeneca Company Information
11.5.2 Astrazeneca Lysosomal Storage Disease (LSD) Product Offered
11.5.3 Astrazeneca Lysosomal Storage Disease (LSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Astrazeneca Main Business Overview
11.5.5 Astrazeneca Latest Developments
11.6 Biomarin Pharmaceutical
11.6.1 Biomarin Pharmaceutical Company Information
11.6.2 Biomarin Pharmaceutical Lysosomal Storage Disease (LSD) Product Offered
11.6.3 Biomarin Pharmaceutical Lysosomal Storage Disease (LSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Biomarin Pharmaceutical Main Business Overview
11.6.5 Biomarin Pharmaceutical Latest Developments
11.7 Eli Lilly
11.7.1 Eli Lilly Company Information
11.7.2 Eli Lilly Lysosomal Storage Disease (LSD) Product Offered
11.7.3 Eli Lilly Lysosomal Storage Disease (LSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Eli Lilly Main Business Overview
11.7.5 Eli Lilly Latest Developments
11.8 Lexicon Pharmaceuticals
11.8.1 Lexicon Pharmaceuticals Company Information
11.8.2 Lexicon Pharmaceuticals Lysosomal Storage Disease (LSD) Product Offered
11.8.3 Lexicon Pharmaceuticals Lysosomal Storage Disease (LSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Lexicon Pharmaceuticals Main Business Overview
11.8.5 Lexicon Pharmaceuticals Latest Developments
11.9 Novo Nordisk
11.9.1 Novo Nordisk Company Information
11.9.2 Novo Nordisk Lysosomal Storage Disease (LSD) Product Offered
11.9.3 Novo Nordisk Lysosomal Storage Disease (LSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Novo Nordisk Main Business Overview
11.9.5 Novo Nordisk Latest Developments
11.10 Merck
11.10.1 Merck Company Information
11.10.2 Merck Lysosomal Storage Disease (LSD) Product Offered
11.10.3 Merck Lysosomal Storage Disease (LSD) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Merck Main Business Overview
11.10.5 Merck Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.